Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable persons between age of 18-60~* Available during the trial period and for follow-up~* Able to read, understand, and sign informed consent~* Able to be contacted by telephone for follow-up of adverse events~Exclusion Criteria:~* Use of experimental vaccines within the month prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products during the duration of the study.~* Receipt of immunoglobulin or other blood product within 3 months prior to enrollment~* Receipt of other licensed vaccines within the preceding 4 weeks~* History of a severe reaction following influenza vaccination~* Use of cytotoxic therapy or biologic modifiers in the previous 2 years.~* Plans to receive cytotoxic therapy during the study period.~* Concurrent acute moderate to severe illness. (Vaccination will be deferred until recovery. Subjects with mild illnesses with fever ≤37.8ºC orally may be enrolled).~* History of medical disorder associated with immunosuppression (eg. including HIV-infected individuals, transplant recipients)~* History of chronic lung, cardiac, renal or liver disease, which has required hospitalization in the last year.~* Receipt of any high-dose daily systemic corticosteroids (inhaled steroids are acceptable) within two weeks of study entry. High dose is defined as a dose of 20 mg of prednisone daily or its equivalent. Topical steroids are allowed.~* Failure to give written, informed consent~* History of febrile illness (\>37.8ºC orally) within the past 72 hours (immunization may be deferred).~* Known allergy to eggs or other components of vaccine (i.e., thimerosal)~* History of Guillain-Barré Syndrome (GBS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Intanza - self-administered (Type: ACTIVE_COMPARATOR): Self-administered intradermal influenza vaccine
- Intanza - nurse-administered (Type: ACTIVE_COMPARATOR): Nurse-administered intradermal influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).